Aktis Oncology, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
AKTS$17.45+6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three months ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows used in operating activities | ||
| Net loss | $(18,325) | $(14,985) |
| Adjustments to reconcile net loss to net cash flows used in operating activities: | ||
| Depreciation and amortization | 652 | 484 |
| Stock-based compensation | 3,022 | 1,235 |
| Net amortization of premiums and accretion of discounts on investments in marketable securities | (529) | (1,854) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (828) | 701 |
| Interest receivable | (1,105) | 195 |
| Operating lease right-of-use assets | 191 | 222 |
| Other assets | (1,877) | 515 |
| Accounts payable | (65) | 90 |
| Accrued expenses and other current liabilities | (1,824) | (2,219) |
| Operating lease liabilities | (327) | (418) |
| Deferred revenue | (3,227) | (1,448) |
| Net cash used in operating activities | (24,242) | (17,482) |
| Cash flows provided by investing activities | ||
| Purchases of marketable securities | — | (10,816) |
| Proceeds from maturities of marketable securities | 22,395 | 51,750 |
| Purchases of property and equipment | (1,854) | (1,893) |
| Net cash provided by investing activities | 20,541 | 39,041 |
| Cash flows provided by (used in) financing activities | ||
| Proceeds from initial public offering, net of underwriter discounts and commissions paid during the period | 339,780 | — |
| Payment of offering costs | (2,263) | (518) |
| Proceeds from exercise of common stock options | 30 | 50 |
| Net cash provided by (used in) financing activities | 337,547 | (468) |
| Net increase in cash, cash equivalents and restricted cash equivalents | 333,846 | 21,091 |
| Cash, cash equivalents and restricted cash equivalents at beginning of period | 38,933 | 38,308 |
| Cash, cash equivalents and restricted cash equivalents at end of period | $372,779 | $59,399 |
| Reconciliation of cash, cash equivalents and restricted cash equivalents | ||
| Cash and cash equivalents | $371,630 | $58,250 |
| Long-term restricted cash equivalents | 1,149 | 1,149 |
| Total cash, cash equivalents and restricted cash equivalents | $372,779 | $59,399 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Remeasurement of right-of-use asset and lease liability due to lease modification | $— | $370 |
| Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering | $333,409 | $— |
| Deferred offering costs transferred to additional paid in capital | $4,456 | $— |
| Purchases of property and equipment included in accounts payable | $32 | $— |
| Purchases of property and equipment included in accrued expenses | $152 | $1,196 |
| Net unrealized loss on marketable securities | $(283) | $(58) |
| Deferred offering costs included in accrued expenses | $— | $332 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.